This is called, increased intestinal permeability in the medical literature and leaky gut in the lay press.[1] An example of this process can be seen in Celiac Disease and Non-Celiac Gluten Sensitivity
Consequently, the targeted inhibition of GOT1, in conjunction with its upstream and downstream pathways, or the combined inhibition of the major metabolic pathways of glutamine, has emerged as a promising novel strategy to overcome metabolic therapy resistance
doi:10.1159/000350185 Marx W, Ried K, McCarthy AL, et al
Because injuries, inflammation, and even long-term wear and tear can slow you downbut BPC-157 helps your body heal itself faster, better, and stronger
Most research involves animal studies, and the Phase 1 human trial completed in 2015 never published results